Entac Medical LLC

Entac Medical LLC develops wearable technology focusing on digital health solutions that utilize predictive analytics and artificial intelligence to enhance patient monitoring and care. Founded in 2011 and headquartered in Germantown, US, Entac Medical LLC specializes in digital health solutions through advanced wearable devices. Buddy Lyons, the founder and CEO, has previously launched other ventures. The firm has successfully raised a total of USD 0.

52 mn through a Series A funding round on May 3, 2018, led by Innova Memphis, bringing the current company valuation to USD 3. 12 mn. The company has engaged in a total of 4 deals to date. Entac Medical specializes in developing advanced wearable device technology, with a focus on digital health solutions that leverage predictive analytics and artificial intelligence.

Their core offerings include the PrevisEA™ and Previs™ CDP, which utilize biological acoustic signals to anticipate adverse patient events, aiming to enhance patient outcomes by preventing hospital readmissions and reducing healthcare costs. The company primarily serves healthcare providers and institutions in the United States and Europe, assisting in managing gastrointestinal impairments and optimizing postoperative care, targeting patients recovering from surgery and medical professionals seeking improved patient monitoring efficiency. Entac Medical's revenue model revolves around business-to-business transactions, focusing on partnerships with healthcare facilities. The company directly sells its flagship products, PrevisEA™ and Previs™ CDP, to hospitals and clinics, integrating these devices into patient care protocols.

Pricing reflects the technology's value in improving patient outcomes and reducing readmission rates, with possible subscription models for ongoing software support and analytics. Revenue generation is closely linked to the adoption of their technology and its effectiveness in clinical settings. Entac Medical plans to leverage its recent Series A funding to further develop its product line, including upcoming enhancements to the PrevisEA™ and Previs™ CDP devices, although specific launch dates have not been disclosed. The company aims to expand its market presence in Europe and other regions by 2023, focusing on partnerships that enhance the use of wearable technology in clinical environments.

The funding obtained in May 2018 will support these initiatives and help drive growth in new markets.